MRA Advisory Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$994K Buy
859
+567
+194% +$669K 0.37% 45
2026
Q2
$350K Sell
292
-739
-72% -$755K 0.13% 104
2026
Q1
$949K Buy
1,031
+45
+5% +$45.6K 0.39% 48
2025
Q4
$1.06M Buy
986
+147
+18% +$141K 0.44% 38
2025
Q3
$640K Sell
839
-135
-14% -$100K 0.28% 53
2025
Q2
$760K Buy
974
+109
+13% +$84.7K 0.36% 38
2025
Q1
$714K Sell
865
-665
-43% -$553K 0.38% 35
2024
Q4
$1.18M Buy
1,530
+351
+30% +$291K 0.63% 28
2024
Q3
$1.04M Sell
1,179
-137
-10% -$123K 0.57% 27
2024
Q2
$1.19M Buy
1,316
+140
+12% +$112K 0.68% 24
2024
Q1
$915K Buy
1,176
+328
+39% +$233K 0.55% 26
2023
Q4
$495K Buy
+848
New +$495K 0.33% 46

Other funds holding LLY

MRA Advisory Group's LLY Position: Q3 2026 in Review

MRA Advisory Group increased its Eli Lilly (LLY) stake by 194% in Q3 2026, buying an estimated $669K and bringing the position to 859 shares worth $994K. The position accounts for 0.37% of the portfolio, ranked #45.

MRA Advisory Group first reported a position in LLY in Q4 2023 and has held it in 12 quarters since. The position peaked at $1.19M in Q2 2024. 1,879 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • MRA Advisory Group held 859 shares of Eli Lilly worth $994K as of Q3 2026.
  • MRA Advisory Group bought 567 Eli Lilly shares in Q3 2026, an estimated $669K.
  • Eli Lilly made up 0.37% of MRA Advisory Group's portfolio in Q3 2026, its #45 holding.
  • MRA Advisory Group first reported a position in Eli Lilly in Q4 2023 and has held it in 12 quarters since.
  • MRA Advisory Group's Eli Lilly position peaked at $1.19M in Q2 2024.
  • 1,879 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on MRA Advisory Group's 13F filing for Q3 2026, filed 7 Oct 2026.